All In Biotech

Drug Trial Radar · NCT02653898

Malaria Elimination Pilot Study in Military Forces in Cambodia

Defining Effective, Appropriate, Implementable Strategies for Malaria Elimination in Military Forces in Cambodia as a Model for Mobile Populations

Last checked: Nov 20, 2026Latest source record: Mar 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,050 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,050

Actual

Start

Jan 2016

Primary completion

Aug 2016

Study completion Dec 2021

Sponsor

Sponsor type
Government (non-federal)
Collaborators
National Center for Parasitology, Entomology, and Malaria Control (CNM); Ministry of National Defense, Royal Cambodian Armed Forces Department of Health
First posted
Jan 13, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 2 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Antimalarial drug resistance has reached critical levels on the Thai-Cambodian border. Many have begun advocating for concerted malaria elimination efforts in Cambodia. However, there is currently no consensus on how malaria elimination is to be achieved with the tools available. In this study, the investigators will conduct operational research with the Royal Cambodian Armed Forces (RCAF) and National Malaria Center (CNM) to quantify the relative effectiveness of the two major interventional approaches - monthly malaria prophylaxis (MMP) or focused screening and treatment (FSAT) - in a head to-head comparison. In addition, the investigators will quantify the relative contribution of a recently advocated vector intervention for military personnel - the insecticide treated uniform (ITU) - in addition to other vector control measures currently employed by the RCAF. The investigators will employ the same permethrin insecticide self-application kits currently used by the US military. The investigators will estimate the cost effectiveness of each approach and attempt to define the best way forward for malaria elimination efforts in a critically important malaria reservoir in military population (and their dependents) who reside on the Thai-Cambodian border. The aim of the study is not only to conduct research to better define the best way forward in malaria elimination efforts in the high risk military populations, but to also build capacity within the RCAF to support and lead future elimination efforts in the most difficult-to-reach mobile populations.

Conditions

  • Malaria
  • Parasitic Diseases

Interventions

  • DHA-PIPDrug

    Administered monthly (weight-based) on days 1-3, during months 1, 2, and 3 in the MMP arm and also as a first line agent for P.v malaria recurrence in both MMP and FSAT treatment arms

  • PrimaquineDrug

    22.5 mg weekly for 12 weeks in the MMP arm; low dose primaquine (15mg) for transmission blocking of P. falciparum or 14 days of primaquine (15mg) in G6PD normal volunteers or 8 weeks of low dose primaquine (45mg) in G6PD-deficient volunteers for radical cure of P. vivax

  • Artesunate + MefloquineDrug

    Weight based; first line agent for P.f malaria infection diagnosed at monthly follow ups, administered on days 1-3 in subjects with malaria recurrence

  • Permethrin (Insecticide treated uniform)Drug

    40% Permethrin IDA kit, applied once to the uniforms for volunteers assigned to ITU arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The absolute risk reduction based on the proportion of subjects remaining malaria-free at the end of 6 months between the study arms as diagnosed by PCR-corrected malaria microscopyTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • RCAF treatment facilities

    Anlong Veaeng, Oddar Meancheay, Cambodia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.